Inflection Biosciences Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $571K

  • Investors
  • 4

Inflection Biosciences General Information

Description

Developer of small molecule therapeutics intended to help in the treatment of cancer. The company's therapeutics offer treatments for autoimmune and inflammatory diseases, solid tumors, and hematological malignancies, enabling healthcare providers to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Suite 15, Anglesea House
  • Carysfort Avenue, Blackrock
  • Dublin A94 X209
  • Ireland
+353 (01) 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inflection Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 18-May-2023 $571K 00.000 00.00 Completed Generating Revenue
4. Later Stage VC 11-Aug-2019 00000 000 00.000 Completed Pre-Clinical Trials
3. Later Stage VC 10-Apr-2018 000 00.000 00.000 Completed Pre-Clinical Trials
2. Early Stage VC 09-Mar-2015 $913K $1.53M 00.000 Completed Pre-Clinical Trials
1. Seed Round 04-Jun-2013 $615K $615K Completed Startup
To view Inflection Biosciences’s complete valuation and funding history, request access »

Inflection Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary A 00 00.000000 0000.00 0000.00 00 0000.00 0.000
Ordinary 12,558 $0.010997 $181.49 $181.49 1x $181.49 4.66%
Ordinary 1,552 $0.010997 $153.99 $153.99 1x $153.99 4.81%
To view Inflection Biosciences’s complete cap table history, request access »

Inflection Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule therapeutics intended to help in the treatment of cancer. The company's therapeutics offer t
Drug Discovery
Dublin, Ireland
6 As of 2023
00.000
00.00 0000-00-00
0000000000 0 00.000

000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Seattle, WA
00 As of 0000
00000
000000000 00000

000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pari
0000 000000000
Barcelona, Spain
00 As of 0000
000.00
000.00 0000-00-00
0000000 0000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inflection Biosciences Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kineta Formerly VC-backed Seattle, WA 00 00000 000000000 00000
Ability Pharma Private Equity-Backed Barcelona, Spain 00 000.00 0000000 0000 000.00
Cyteir Therapeutics Formerly VC-backed Lexington, MA 00 00000 00000000 00000
AM-Pharma Venture Capital-Backed Utrecht, Netherlands 00 00000 00000000000 00000
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

Inflection Biosciences Executive Team (6)

Name Title Board Seat Contact Info
Darren Cunningham Co-Founder, Chief Executive Officer & Board Member
Gemma Carroll Financial Controller
Michael O'Neill Ph.D Co-Founder, Director of Research and Development & Board Member
Murray Yule Ph.D Chief Medical Officer
Shaun McNulty Ph.D Chief Scientific Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Inflection Biosciences Board Members (7)

Name Representing Role Since
Conor Mallaghan Self Board Member 000 0000
Darren Cunningham Inflection Biosciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Gregory I. Berk MD Self Board Member 000 0000
John Lynch Self Board Member 000 0000
Michael O'Neill Ph.D Inflection Biosciences Co-Founder, Director of Research and Development & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Inflection Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inflection Biosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bacchantes Venture Capital Minority 000 0000 000000 0
Fountain Healthcare Partners Venture Capital Minority 000 0000 000000 0
Michael Smurfit Angel (individual) Minority 000 0000 000000 0
Enterprise Ireland Venture Capital Minority 000 0000 000000 0
To view Inflection Biosciences’s complete investors history, request access »

Inflection Biosciences FAQs

  • When was Inflection Biosciences founded?

    Inflection Biosciences was founded in 2012.

  • Who is the founder of Inflection Biosciences?

    Darren Cunningham, Michael O'Neill Ph.D, and John Scanlan Ph.D are the founders of Inflection Biosciences.

  • Who is the CEO of Inflection Biosciences?

    Darren Cunningham is the CEO of Inflection Biosciences.

  • Where is Inflection Biosciences headquartered?

    Inflection Biosciences is headquartered in Dublin, Ireland.

  • What is the size of Inflection Biosciences?

    Inflection Biosciences has 6 total employees.

  • What industry is Inflection Biosciences in?

    Inflection Biosciences’s primary industry is Drug Discovery.

  • Is Inflection Biosciences a private or public company?

    Inflection Biosciences is a Private company.

  • What is the current valuation of Inflection Biosciences?

    The current valuation of Inflection Biosciences is 00.00.

  • What is Inflection Biosciences’s current revenue?

    The current revenue for Inflection Biosciences is 000000.

  • How much funding has Inflection Biosciences raised over time?

    Inflection Biosciences has raised $3.57M.

  • Who are Inflection Biosciences’s investors?

    Bacchantes, Fountain Healthcare Partners, Michael Smurfit, and Enterprise Ireland have invested in Inflection Biosciences.

  • Who are Inflection Biosciences’s competitors?

    Kineta, Ability Pharma, Cyteir Therapeutics, AM-Pharma, and Voyager Therapeutics are some of the 21 competitors of Inflection Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »